Acarbose efficacy

In a comparison of voglibose and acarbose in 21 in-patients with type 2 diabetes who took part in a randomized crossover study of acarbose 150 mg/day and voglibose 0.9 mg/day, there was marked interindividual variation in response (18). For both drugs efficacy was better in those with gastrointestinal adverse effects, such as abdominal distention and flatulence. 

Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes data from a 2-year surveillance study. Diabetes Res Clin Pract 1998 40(l) 63-70. 

Hanefeld M, Bar K. Efficacy and safety of combined treatment of type 2 diabetes with acarbose and metformin. Diabetes Stoffwechsel 1998 7 186-90. 

Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus. A post marketing surveillance study Clin Drug Invest 2005 25 651-9. 

Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002 55(2) 99-103. 

Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998 21(12) 2056-61. 

Riccardi G, Giacco R, Parillo M, Turco S, Rivellese AA, Ventura MR, Contadini S, Marra G, Monteduro M, Santeusanio F, Brunetti P, Librenti MC, Pontiroli AE, Vedani P, Pozza G, Bergamini L, Bianchi C. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus a placebo-controlled, double-blind, multicentre study. Diabet Med 1999 16(3) 228-32. 

Segal P, Eliahou HE, Petzinna D, Neuser D, Bruckner A, Spengler M. Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clin Drug Invest 2005 25 589-95. 

ACARBOSE PANCREATIN Theoretical risk of 1 efficacy of acarbose 1 absorption Watch for poor response to acarbose monitor capillary blood glucose closely... 

In long-term studies of over 6 (Hanefeld et al., 1990, 1991) and 12 months (Aubell et al., 1983), fasting and postprandial blood glucose levels were significantly reduced compared with diet alone (Table 8). HbAi was lowered from 9.2 to 8.6%. Other investigators reported a decrease of HbA[ from 10.8 to 8.5% following 6 months of treatment with 3 x 100 mg acarbose daily. There were no changes noted in the efficacy of acarbose. 

The therapeutic effects of acarbose and biguanides have been compared in Type-II diabetics (Pagano and Cavallo-Perin, 1990) and found to be nearly equally effective. The same was true in studies (by Schwedes et al. (1982), who compared acarbose and metformin in poorly controlled NIDDM, while Schoffling et al. (1982) reported that acarbose was even more effective than metformin. Drost et al. (1982) concluded from their studies, however, that there was no basic difference between the hypoglycaemic effects of acarbose and metformin. Petersen (1982) tested the efficacy of acarbose versus buformin in NIDDM. Acarbose was found to reduce postprandial but not fasting blood glucose levels and to be slightly less effective than buformin. 

Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-contrelled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995 18 928-932. 

May C. Efficacy and tolerabihty of step wise increasing dosage of acarbose in patients with non-insuhn-dependent diabetes (NIDDM) treated with suUbnylureas. Diabetes Stoffwechsel 1995 4 3-7. 

Fischer S, Hanefeld M, Spengler M et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus efficacy and safety of low and high doses. 1998 35 34. 

Neomycin may increase the efficacy and the gastrointestinal adverse effects of acarbose. There is some indirect evidence that acarbose with alcohol may increase the hepatotoxicity of paracetamol (acetaminophen). Parafytic ileus has been reported in a Japanese patient treated with acarbose and promethazine, an an-timuscarinic drug. 

---